Medtronic Expands Minimally Invasive Surgery Line With AF, Valve Products
This article was originally published in The Gray Sheet
Medtronic is developing a clinical trial for a minimally invasive ablation device for non-concomitant treatment of atrial fibrillation, or lone AF
You may also be interested in...
Edwards Lifesciences intends to resume a U.S. PVT percutaneous aortic valve feasibility trial by year-end
CoreValve plans to begin a 250-patient European pivotal trial of its ReValving self-expanding percutaneous aortic valve replacement system by year-end
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.